Somatostatin

Yamada, Tadataka; Chiba, Tsutomu

doi:10.1002/cphy.cp060219

Cited by 9 publications

(2 citation statements)

References 265 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SRIF was first described to be present in ovine hypothalamus (Brazeau et al , 1973) but was demonstrated later to be distributed throughout the body. SRIF is found in the central nervous system, pancreas, stomach and in the gut (Reichlin, 1983; Epelbaum, 1986; Yamada & Chiba, 1989). SRIF was also demonstrated to be present in lung tissue of various species.…”

Section: Introductionmentioning

confidence: 99%

Identification and pharmacological characterization of somatostatin receptors in rat lung

Schloos

Raulf

Hoyer

et al. 1997

British J Pharmacology

View full text Add to dashboard Cite

SRIF-28 to rat lung membranes was inhibited by SRIF-14, SRIF-28 and dierent SRIF analogues. SRIF and dierent synthetic short chain SRIF analogues exhibited the following rank order of potency: SRIF-284SRIF-144CGP 2399644RC 1604BIM 230144SMS 201-9954BIM 230564MK 678. 6 The binding anities for SRIF and the various SRIF analogues determined using rat lung tissue were in close correlation to those obtained with Chinese hamster ovary (CHO) cells stably expressing sst 1 (r=0.92) and sst 4 (r=0.95) receptors, respectively. 7 Reverse transcriptase -polymerase chain reaction (RT-PCR) showed the predominant expression of mRNA speci®c for sst 4 receptors as well as some weak sst 1 mRNA expression. 8 The ®ndings suggest that sst 4 receptor expression is the predominant form of the somatostatin receptors identi®ed in rat lung tissue. In this study we demonstrated for the ®rst time the existence of sst 4 receptors in mammalian tissue.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification and pharmacological characterization of somatostatin receptors in rat lung

Schloos

Raulf

Hoyer

et al. 1997

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Somatostatin has been shown to inhibit intracellular cAMP production and to block the secretory events in various secretory cells [8], Recent studies have revealed some other mechanisms governing the inhibitory actions of somatostatin. In canine gastric parietal cells [9], soma tostatin inhibited acid secretion induced by exogenous administration of cAMP analogues.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Somatostatin Analogue Octreotide on Amylase Secretion from Mouse Pancreatic Acini

Ishiguro¹,

Hayakawa²,

Kondo³

et al. 1993

Digestion

View full text Add to dashboard Cite

To clarify whether somatostatin has an inhibitory effect on pancreatic acinar cells, we studied the effect of a long-acting analogue of somatostatin, octreotide, on amylase secretion from isolated mouse pancreatic acini. Octreotide (100 nM) had no inhibitory effects on amylase secretion stimulated by secretin or vasoactive intestinal polypeptide (VIP), while reducing the increase of cyclic adenosine 3´,5´-monophosphate (cAMP). On the other hand, octreotide inhibited synergistic amylase secretion induced by secretin or VIP in combination with cholecystokinin (CCK). Octreotide also reduced synergistic amylase secretion by secretin or VIP in combination with calcium ionophore A23187. CCK and A23187 did not alter the increase of cAMP induced by secretin and the inhibitory effect of octreotide on cAMP production. Octreotide did not significantly inhibit amylase secretion stimulated by dibutyryl cAMP (dbcAMP) alone, but reduced synergistic amylase secretion by dbcAMP+A23187. Results obtained above reveal that octreotide has a direct inhibitory effect on amylase secretion from mouse pancreatic acini and probably affects stimulus secretion coupling at a point distal to the production of cAMP, besides inhibiting adenylate cyclase.

show abstract

Biochemistry and physiology of gastrointestinal somatostatin

Lucey

Yamada

1989

Digest Dis Sci

Self Cite

View full text Add to dashboard Cite

Somatostatin, a tetradecapeptide initially isolated from the ovine hypothalamus, is widely distributed throughout the gastrointestinal tract where it may act as a hormone, local chemical messenger, or neurotransmitter to elicit many physiological actions. Release of somatostatin from D cells in the gut is regulated by mechanisms that are both dependent on and independent of cAMP. In most cases somatostatin acts to inhibit the function of its target cells. It performs this action in part via pertussis-toxin-sensitive inhibitory guanine nucleotide-binding proteins that regulate adenylate cyclase activity. Other mechanisms may involve sites of action distal to intracellular second messenger systems.

show abstract

Somatostatin

Cited by 9 publications

References 265 publications

Identification and pharmacological characterization of somatostatin receptors in rat lung

Identification and pharmacological characterization of somatostatin receptors in rat lung

The Effect of Somatostatin Analogue Octreotide on Amylase Secretion from Mouse Pancreatic Acini

Biochemistry and physiology of gastrointestinal somatostatin

Contact Info

Product

Resources

About